ETCTN Trials by Disease/Treatment Area: Leukemia

**Lymphocytic**
- Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia
  - ▼ 10030: A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia

**Myelogenous**
- Relapsed or refractory AML, myelodysplastic syndrome, or Chronic Myelomonocytic Leukemia
  - ▼ 10026: A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
  - 10247: A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
  - ▼ 10246: A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
  - 10237: A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents

**Myelodysplastic Syndrome**
- AML with wild-type p53
  - 10075: A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia

**Hematologic Malignancy**
- AML in complete remission
  - 9706: Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)

**AML with 11q23 rearrangement or NPM1 mutation**
- AML/ myeloid malignancy with 11q23 rearrangement or NPM1 mutation
  - ▼ 10200: A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

**AML with 11q23 or KMT2A (MLL) rearrangement**
- AML with 11q23 or KMT2A (MLL) rearrangement
  - ▼ 10212: A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with MLL Rearrangement

**AML (front line therapy)**
- AML (front line therapy)
  - ▼ 1009: A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure

**MDS or oligoblastic AML**
- MDS or oligoblastic AML
  - 10014: A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

**Hematologic Malignancy, NOS**
- Hematologic malignancy, NOS
  - ▼ 10273: A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia
  - ▼ 10264: The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

**AML in complete remission**
- AML associated with antecedent myeloproliferative disorder

**AML with wild-type p53**
- AML with wild-type p53

**Myelodysplastic Syndrome**
- AML with wild-type p53

**Hematologic Malignancy**
- AML with wild-type p53

**Hematologic Malignancy, NOS**
- AML with wild-type p53

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: March 13, 2019